论文部分内容阅读
目的探讨作为卵巢癌标记物的血清人附睾蛋白4(HE4)在卵巢癌诊断过程中的作用。方法选择100例EOC患者、45例卵巢非癌症患者、65例其他肿瘤患者及100名健康对照者血清作为实验样本,应用酶联免疫吸附测定法(ELISA)测定HE4浓度水平。结果 EOC患者血清HE4水平显著高于健康组和卵巢非癌症患者;以健康对照组的P95(percent 95)值为参考值,月经正常者HE4检测的Cut-off值为58.2pmol/L,灵敏度57.5%,特异度93.9%;月经消失者HE4检测的Cut-off值为67.6pmol/L,灵敏度80.3%,特异度86.4%。卵巢癌患者血清HE4浓度随着肿瘤的发生发展而不断升高,淋巴结未转移者HE4水平明显低于转移患者。同时对28例EOC患者的血清样本进行了检测,HE4浓度的变化与疾病的发展趋势有着非常密切的关系;HE4浓度变化与病情发展吻合率达到82.2%(23/28)。治疗后,患者HE4水平显著下降(21/25)。结论 HE4检测在EOC诊断及治疗方面具有较好的临床应用前景。
Objective To investigate the role of serum human epididymis 4 (HE4) as a marker of ovarian cancer in the diagnosis of ovarian cancer. Methods Serum samples of 100 patients with EOC, 45 patients with ovarian non-cancer, 65 patients with other tumors and 100 healthy controls were selected as experimental samples. HE4 concentration was determined by enzyme-linked immunosorbent assay (ELISA). Results The serum HE4 level in EOC patients was significantly higher than that in healthy patients and non-ovarian cancer patients. The cut-off value of HE4 with normal menstruation was 58.2 pmol / L and the sensitivity was 57.5 % And specificity of 93.9%. The cut-off value of HE4 in patients with disappearance of menstruation was 67.6pmol / L, the sensitivity was 80.3% and the specificity was 86.4%. The serum level of HE4 in patients with ovarian cancer increased with the occurrence and development of tumors, and the levels of HE4 in patients with lymph node metastasis were significantly lower than those in patients with metastasis. At the same time, the serum samples of 28 EOC patients were tested. The change of HE4 concentration was closely related to the development trend of the disease. The coincidence rate of HE4 concentration and disease development was 82.2% (23/28). After treatment, the patient’s HE4 level decreased significantly (21/25). Conclusion The detection of HE4 has a good clinical application in the diagnosis and treatment of EOC.